Shanghai Celgen Bio-Pharmaceutical Co.,Ltd   Report issue

For profit Phase 3
Founded: Shanghai China (2000)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2015
NCT02701205
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

etanercept (enbrel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1